The role of P2X7 receptor in ATP-mediated human leukemia cell death: calcium influx-independent.
Activation of the P2X7 receptor leads to a rapid, bidirectional flux of cations, causing broad range of biological responses including cytotoxicity. However, the mechanism of P2X7-mediated cytotoxicity remains largely unexplored. In our previous study, the lack of P2X7-mediated calcium response under normal conditions was found in P2X7(+) hematopoietic cell lines. In this study, the P2X7-mediated cytotoxicity in different type of cells (P2X7(-), P2X7(+) with calcium response, and P2X7(+) without calcium response) was investigated. Our results showed that P2X7 agonists, adenosine 5'-triphosphate (ATP) or 2',3'-O-(4 benzoylbenzoyl)-ATP, dose-dependently reduced the cell viability in all P2X7(+) cells tested, including J6-1, LCL, and Namalva cells which are negative for P2X7-mediated calcium response, although these effects were lower than those observed in KG1a cells which has normal P2X7 functions. The cytotoxic effect could be blocked by P2X7 antagonists, oxidized ATP and 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine. In addition, externalization of phosphatidylserine could be detected in a time-dependent manner and apoptotic morphological changes could be observed after the activation of P2X7 receptor in J6-1 cells. Furthermore, P2X7-mediated pore formation could be detected in KG1a and J6-1 cells under low-ionic conditions, but not under low-divalent conditions. These effects could not be observed in P2X7(-) Ramos cells. These results suggested that P2X7 receptor-mediated cytotoxic effects may occur independent of calcium response.
Zhang
Xiujun
X
Department of Life Sciences, North China Coal Medical University, Tangshan, China. zhangxiujun66@yahoo.com.cn
Meng
Lijun
L
He
Baoling
B
Chen
Jing
J
Liu
Peng
P
Zhao
Jie
J
Zhang
Yufen
Y
Li
Ming
M
An
Dong
D
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001583:Benzoxazoles / Q000493:pharmacokinetics; D001692:Biological Transport / Q000187:drug effects; D002118:Calcium / Q000378:metabolism*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D007938:Leukemia / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011806:Quinolinium Compounds / Q000493:pharmacokinetics; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D058486:Receptors, Purinergic P2X7; D013050:Spectrometry, Fluorescence; D013997:Time Factors
D001583:Benzoxazoles; C546468:P2RX7 protein, human; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011806:Quinolinium Compounds; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; C089813:YO-PRO 1; C033901:3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate; C017199:2',3'-dialdehyde ATP; C063302:KN 62; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000255:Adenosine Triphosphate; D002118:Calcium